Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial

ChEBI2015-08-27 更新2026-07-12 收录

系统性硬皮病治疗

靶向药物临床试验

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-65405 数据链接链接失效反馈

官方服务：

资源简介：

Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial

创建时间：

2015-08-27

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

神经内分泌肿瘤治疗

靶向药物临床试验

This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started t

NIAID Data Ecosystem60

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

转移性结直肠癌治疗

靶向药物临床试验

Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block t

NIAID Data Ecosystem30

A Phase II Open-label, randomised, parallel group, non comparative study of ZD1839 (IressaTM) and Docetaxel (Taxotere) as second line therapy in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.

非小细胞肺癌治疗

靶向药物临床试验

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promot

DataCite Commons2024-12-02 更新10

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

结直肠癌肝转移术前治疗

靶向药物临床试验

This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery. Monoclonal ant

NIAID Data Ecosystem50

An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.

甲状腺髓样癌

靶向药物临床试验

The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinom

DataCite Commons2025-06-01 更新10

Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial

资源简介：

相关数据集